HKGCC GBA Mission to Guangzhou Explore Opportunities in Healthcare
HKGCC had organized a one-day mission to Guangzhou on 27 February 2025. This visit had included site tours of key enterprises and projects in the health and medical sectors, as well as opportunities to explore potential business ventures in the biopharmaceutical and health industries.
Guangzhou had strategically positioned itself as a global hub for biopharmaceutical innovation and industrial development, attracting leading companies worldwide. These firms had established production facilities, research and development centres, and regional headquarters in the city. At that time, Guangzhou had been home to over 6,500 enterprises in the biopharmaceutical and health sectors, ranking third nationwide. In the first three quarters of 2023, the value added by Guangzhou's biopharmaceutical and health industries had reached RMB 124.182 billion, indicating continuous growth in the sector's scale.
Hong Kong had favorable conditions for developing its life and health industries. It could have enhanced integration with the Greater Bay Area's institutional and systemic frameworks in pharmaceuticals, patents, and medical devices. Hong Kong enterprises should have taken advantage of these emerging opportunities to promote cross-border medical collaboration within the Greater Bay Area.
To explore the latest advancements in Guangzhou's life and health industries, the China Committee and the Health and Wellness Working Group had organized a mission to Guangzhou on 27 February. This visit had included site tours of key enterprises and projects in the health and medical sectors, as well as opportunities to explore potential business ventures in the biopharmaceutical and health industries.
